NDMC101
Based on 1 Customer Validation
NDMC101 is a potent osteoclastogenesis inhibitor and inhibits osteoclast differentiation via down-regulation of NFATc1-modulated gene expression. NDMC101 is similar to the DPP4 substrate and is a significant inhibitor of early T-cell activation via DPP4 inhibition. NDMC101can be used for study of bone disorders, such as rheumatoid arthritis, and synovial inflammation et al.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.91%
- CAS No.: 1308631-40-4
- Formule: C13H9ClFNO2
- Masse moléculaire:265.67
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-A0023
Alogliptin Benzoate
-
HY-B0422
Nateglinide
-
HY-13749
Sitagliptin
-
HY-A0023R
Alogliptin Benzoate (Standard)
-
HY-14291
Vildagliptin
-
HY-10284S
Linagliptin-d4
-
HY-A0023A
Alogliptin
-
HY-15408
Trelagliptin
-
HY-14621
Zingerone
-
HY-32735
Triptolide
-
HY-13749B
Sitagliptin phosphate monohydrate
-
HY-15408A
Trelagliptin succinate
Activité biologique
|
DPP-4 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RAW264.7 | CC50 |
23.2 μM
Compound: 1a, NDMC101
|
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in survival rate after 24 hrs by MTT assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in survival rate after 24 hrs by MTT assay
|
[PMID: 25200306] |
| RAW264.7 | IC50 |
>10 μM
Compound: NDMC101
|
Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as decrease in TRAP-positive multinucleated cells after 4 days by TRAP staining
Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as decrease in TRAP-positive multinucleated cells after 4 days by TRAP staining
|
[PMID: 26005025] |
| RAW264.7 | IC50 |
10 μM
Compound: 1a
|
Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as reduction in TRAP-positive multinucleated cells level incubated with compound in presence of RANKL for 4 days by TRAP staining based light microscopic analysis rela
Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as reduction in TRAP-positive multinucleated cells level incubated with compound in presence of RANKL for 4 days by TRAP staining based light microscopic analysis rela
|
[PMID: 27089213] |
| RAW264.7 | IC50 |
10 μM
Compound: 1a, NDMC101
|
Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as TRAP+ multinucleated cells level incubated for 4 days by TRAP staining assay
Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as TRAP+ multinucleated cells level incubated for 4 days by TRAP staining assay
|
[PMID: 25200306] |
| RAW264.7 | IC50 |
12.5 μM
Compound: 1a, NDMC101
|
Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as reduction in TRAP activity incubated for 4 days by TRAP staining assay
Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as reduction in TRAP activity incubated for 4 days by TRAP staining assay
|
[PMID: 25200306] |
| RAW264.7 | IC50 |
15 μM
Compound: NDMC101
|
Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells
Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells
|
[PMID: 26005025] |
NDMC101 (10-15 μM) inhibits RANKL-induced osteoclast differentiation of bone marrow-derived macrophages (BMDMs) and RAW 264.7 cells[1]. NDMC101 (15 μM) decreases RANKL-induced expression of the osteoclastogenic genes?Nfatc1,?Acp5,?Ctsk,?Oscar,?Itgb3, and?Dcstamp?in BMDMs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1308631-40-4
-
Appearance Solid
-
Masse moléculaire 265.67
-
Formule C13H9ClFNO2
-
Color White to off-white
-
SMILES
OC1=C(C=CC=C1)C(NC2=CC=C(C=C2F)Cl)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvant et solubilité
DMSO : 100 mg/mL (376.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.41 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Chia-Pi Cheng, et al. A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: a potential osteoclastogenesis inhibitor for experimental arthritis. J Clin Immunol. 2012 Aug;32(4):762-77. [Content Brief]
[2]. Jun-Ting Liou, et al. A salicylate-based small molecule HS-Cm exhibits immunomodulatory effects and inhibits dipeptidyl peptidase-IV activity in human T cells. Eur J Pharmacol. 2014 Mar 5;726:124-32. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7641 mL | 18.8203 mL | 37.6407 mL | 94.1017 mL |
| 5 mM | 0.7528 mL | 3.7641 mL | 7.5281 mL | 18.8203 mL | |
| 10 mM | 0.3764 mL | 1.8820 mL | 3.7641 mL | 9.4102 mL | |
| 15 mM | 0.2509 mL | 1.2547 mL | 2.5094 mL | 6.2734 mL | |
| 20 mM | 0.1882 mL | 0.9410 mL | 1.8820 mL | 4.7051 mL | |
| 25 mM | 0.1506 mL | 0.7528 mL | 1.5056 mL | 3.7641 mL | |
| 30 mM | 0.1255 mL | 0.6273 mL | 1.2547 mL | 3.1367 mL | |
| 40 mM | 0.0941 mL | 0.4705 mL | 0.9410 mL | 2.3525 mL | |
| 50 mM | 0.0753 mL | 0.3764 mL | 0.7528 mL | 1.8820 mL | |
| 60 mM | 0.0627 mL | 0.3137 mL | 0.6273 mL | 1.5684 mL | |
| 80 mM | 0.0471 mL | 0.2353 mL | 0.4705 mL | 1.1763 mL | |
| 100 mM | 0.0376 mL | 0.1882 mL | 0.3764 mL | 0.9410 mL |
NDMC101 Related Classifications
HY-124958 Related Classifications
Powered by Bioz